NCT07100184尚未招募2 期
Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for Patients With HER2-Expressing High-Risk or Very High-Risk Non-Muscle Invasive Bladder Cancer
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 30
- 主要终点
- 12-month disease-free survival (DFS) rate
研究概览
简要总结
This study is an open, single-arm, single-center exploratory clinical study to explore the efficacy and safety of Disitamab Vedotin (RC-48) in combination with radiotherapy for the treatment of patients with HER2-expressing high-risk or very high-risk non-muscle invasive bladder cancer (NMIBC) without visible foci of disease after transurethral resection of bladder tumor (TURBT). The study plans to enroll 30 patients with high or very high risk HER2-expression NMIBC without visible lesions after TURBT. The study includes a screening period, a treatment period, and a survival follow-up period. This is a single-center study conducted at the Peking University First Hospital, and the PI is Prof. CuiJian Zhang.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •voluntarily agree to participate in the study and sign an informed consent form;
- •male or female, age ≥18 years;
- •disease fulfillment:
- •the patient's disease status was determined by at least two associate or chief physicians to be free of visible lesions to the naked eye after transurethral bladder tumor electrodessication;
- •A definitive postoperative pathologic diagnosis of non-muscle invasive bladder cancer with >50% of its major tissue component being uroepithelial carcinoma (migratory cell carcinoma);
- •Completion of TURBT within 4 weeks prior to study administration and completion of immediate chemotherapy infusion (chemotherapy agent is mitomycin);
- •Absence of focal lymph node metastasis as well as distant metastasis confirmed by imaging (including but not limited to thoracoabdominopelvic CT/MR or PET/CT) within 6 weeks prior to enrollment, i.e., N0M0;
- •Subject's NMIBC risk grouping is consistent with a high or very high risk group:
- •patient refuses or is unfit to receive BCG infusion; BCG intolerance or progression of BCG therapy;
- •the subject meets 2+ or 3+ HER2 expression by immunohistochemistry (IHC) of tumor tissue obtained by TURBT within 4 weeks;
- •a score of 0-1 on the ECOG Physical Status Scale;
- •adequate cardiac, bone marrow, hepatic, and renal functions
排除标准
- •combined extravesical (i.e., urethral, ureteral, or renal pelvic) uroepithelial cancer;
- •have received any other antineoplastic therapy, such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc., within 4 weeks prior to study dosing, excluding 1 instillation of chemotherapy completed immediately after TURBT;
- •has not recovered to CECAT 5.0 grade 0-1 from an adverse event caused by a previously applied antineoplastic agent within 2 weeks prior to initiation of study drug administration;
- •who have had major surgery within 4 weeks prior to the start of study dosing or are scheduled to have major surgery during the study period;
- •Serum virology: a) Positive HBsAg with a positive HBVDNA copy number. b) Positive HCVAb with a positive HBVDNA copy number. c) Positive HBsAg with a positive HBVDNA copy number. d) Positive HBsAg with a positive HBV DNA copy number;
- •have received a live vaccine within 4 weeks prior to the start of study drug administration or plan to receive any vaccine during the study period;
- •heart failure classified by the New York Heart Association (NYHA) as Grade 3 or higher;
- •a serious arterial/venous thrombotic event or cardiovascular accident such as deep vein thrombosis, pulmonary embolism, cerebral infarction, cerebral hemorrhage, myocardial infarction, etc., except for lacunar cerebral infarcts, which are asymptomatic and do not require clinical intervention, within the 6 months prior to study dosing;
- •the presence of an active infection requiring systemic therapy, such as active tuberculosis;
- •the presence of systemic diseases or serious comorbidities that, in the judgment of the investigator, are active and not under stable control, including diabetes mellitus, hypertension, cirrhosis of the liver, interstitial pneumonitis, obstructive lung disease, and that would allow subjects to develop complications as a result of receiving intravesical therapy and/or general anesthesia
- •the presence of any other disease, metabolic abnormality, physical examination abnormality, or laboratory test abnormality that, in the judgment of the investigator, gives reason to suspect that the patient has a disease or condition that is unsuitable for the use of the study medication, or that will interfere with the interpretation of the results of the study, or that places the patient at a high risk of developing the study;
- •active autoimmune disease requiring systemic therapy (e.g., use of immunomodulatory agents, corticosteroids, or immunosuppressive agents) was present prior to the initiation of study drug administration, allowing for relevant replacement therapy (e.g., replacement therapy with thyroxine for adrenal or pituitary insufficiency, or physiologic corticosteroids);
- •other malignancies within 5 years prior to the start of study drug administration.
- •a history of previous allogeneic hematopoietic stem cell transplantation or organ transplantation;
- •known hypersensitivity to recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent drugs and their components;
- •pregnant or lactating women;
- •estimated to have insufficient patient compliance for participation in this clinical study.
研究组 & 干预措施
Experimental Arm
Experimental
patients with HER2-expressing high-risk or very high-risk non-muscle invasive bladder cancer (NMIBC) without visible foci of disease after transurethral resection of bladder tumor (TURBT)
干预措施: Disitamab Vedotin combined with Radiotherapy (Drug)
结局指标
主要结局
12-month disease-free survival (DFS) rate
时间窗: 12 months after treatment
Proportion of patients with complete remission confirmed by urine cytology, thoracic-abdominal-pelvic MR, and cystoscopy as a percentage of all patients receiving the full course of medication at 12 months after treatment;
次要结局
- 36-month disease-free survival (DFS) rate(36 months after treatment)
- disease-free survival (DFS)(From the date of initiation of RC48-based therapy until the date of first documented disease recurrence, progression to muscle-invasive bladder cancer, radical cystectomy, or death from any cause, whichever occurs first, assessed up to 60 months.)
- 24-month disease-free survival (DFS) rate(24 months after treatment)
- overall survival (OS)(From the date of initiation of RC48-based therapy until the date of death from any cause, assessed up to 100 months.)
研究者
相似试验
招募中
1 期
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric CancerHER2-low-expressing Gastric CancerGastric CancerNCT06078982Shanghai East Hospital39
招募中
2 期
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerBreast CancerNCT06389006RemeGen Co., Ltd.79
招募中
2 期
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyGastroesophageal Junction AdenocarcinomaGastric CancerNCT06221748RemeGen Co., Ltd.90
尚未招募
4 期
A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial CarcinomaBladder CancerNCT05488353Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University48
招募中
2 期
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II StudyNCT07093866The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School20